Page last updated: 2024-11-11
topopyrone c
Description
topopyrone C: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
topopyrone C : A naphthochromene that is 4H-naphtho[2,3-h]chromene-4,7,12-trione substituted by hydroxy groups at positions 5, 9 and 11 and a methyl group at position 2. It is isolated from fungal strains Phoma and Penicillium and acts as an inhibitor of the enzyme topoisomerase I. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 9884262 |
| CHEMBL ID | 400146 |
| CHEBI ID | 66254 |
| SCHEMBL ID | 16226718 |
| MeSH ID | M0374992 |
Synonyms (9)
| Synonym |
|---|
| topopyrone c |
| CHEMBL400146 |
| chebi:66254 , |
| bdbm50378910 |
| 5,9,11-trihydroxy-2-methyl-4h-naphtho[2,3-h]chromene-4,7,12-trione |
| SCHEMBL16226718 |
| 5,9,11-trihydroxy-2-methylnaphtho[3,2-h]chromene-4,7,12-trione |
| Q15427875 |
| DTXSID701045476 |
Roles (5)
| Role | Description |
|---|
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| antiviral agent | A substance that destroys or inhibits replication of viruses. |
| EC 5.99.1.2 (DNA topoisomerase) inhibitor | A topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA. |
| Penicillium metabolite | Any fungal metabolite produced during a metabolic reaction in Penicillium. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| naphthochromene | An organic heterotetracyclic compound resulting from the formal fusion of a naphthalene with a chromene. |
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| p-quinones | A quinone in which the two oxo groups of the quinone are located para to each other on the 6-membered quinonoid ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (1)
Activation Measurements
Biological Processes (9)
Molecular Functions (5)
Ceullar Components (4)
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID610761 | Binding affinity to weel kinase | 2011 | Journal of natural products, Jun-24, Volume: 74, Issue:6
| Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds. |
| AID610759 | Cytotoxicity against human H460 cells assessed as stimulation of topoisomerase 1-mediated DNA cleavage | 2011 | Journal of natural products, Jun-24, Volume: 74, Issue:6
| Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds. |
| AID314507 | Cytotoxicity against human NCI-H460 cells after 1 hr | 2008 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
| Synthesis and cytotoxic activity of a new series of topoisomerase I inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.87 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.66 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |